ANEB

Healthcare Biotechnology

Anebulo Pharmaceuticals, Inc.

$0.32

-0.00 -0.00% today

Price History

Not enough data

Key Stats

Market Cap

13.05M

Avg Volume

257

EPS

-$0.19

52W High

$2.85

52W Low

$0.00

Div. Yield

0.0%

Valuation

Forward P/E

-0.49

P/B Ratio

1.66

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(69.7%)

Return on Assets

(45.0%)

Liquidity & Leverage

Current Ratio

6.24

Quick Ratio

6.12

Total Cash

9.04M

Total Debt

About

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.